How the Immune System Spots Cancer Cells, and Why It Sometimes Misses Them

Long before a tumor is large enough to show up on a scan, it has often already faced a round of scrutiny from the immune system. The body runs something like a constant inspection process, built to catch cells that look abnormal before they can spread. Understanding how that process works, and where it can be outmaneuvered, explains both why some cancers emerge at all and why certain modern treatments can make the immune system fight back.

How Immune Cells Read the Surface of a Cell

Every cell in the body constantly displays small fragments of its internal proteins on its outer surface, almost like holding up samples of everything happening inside. These fragments are called antigens, and they sit on docking molecules known as MHC class I. Specialized white blood cells called T cells patrol the body checking these displayed fragments. When a cell carries fragments from a mutated or otherwise abnormal protein, a T cell can recognize it as foreign and kill it.

Mutations build up constantly as cells divide, and many produce proteins the immune system has never seen before, which is part of why this system works at all. Some cancer cells, however, find a workaround: they simply stop putting their display molecules on the surface. Without that display, a T cell has nothing to inspect, and it moves on.

That's where a second immune cell type steps in. Natural killer, or NK, cells don't need to recognize a specific antigen first. Instead, they're tuned to notice when a cell's surface display has gone missing altogether, a strategy known as "missing self" recognition. A cell with little or no MHC on its surface looks suspicious to an NK cell even without a specific warning sign. In effect, the two systems cover each other's blind spot: T cells need to see something abnormal, while NK cells react when they see nothing at all.

A Decades-Old Idea, Confirmed in Stages

The notion that immune cells continuously watch for malignant cells isn't new. In 1970, the immunologist Frank Macfarlane Burnet proposed that the immune system performs ongoing surveillance against newly arising cancer cells, catching most of them before they ever become a noticeable tumor. At the time it was mostly a theory, without much direct proof behind it.

Decades later, a research team led by Robert Schreiber built on that idea into a more detailed framework, now generally called cancer immunoediting. It describes the relationship between tumors and the immune system as unfolding in three overlapping phases. In the elimination phase, the immune system detects and destroys abnormal cells as they arise, much as Burnet originally proposed. Some abnormal cells survive this step, though, and enter an equilibrium phase, where the immune system holds them in check without eliminating them completely, sometimes for years. Over time, repeated immune pressure can push surviving cells to pick up changes that let them avoid detection altogether. That's the escape phase, when a tumor becomes capable of outright growth. The framework is a useful way of organizing a very dynamic process, though the precise pace of these phases in human patients is still being worked out.

The Off-Switches Tumors Learn to Use

T cells are powerful, so the body keeps safeguards in place to stop them from attacking normal tissue by mistake. These safeguards are called immune checkpoints: molecular brakes that dial down a T cell's activity once it has done its job. Without checkpoints like this, immune responses could spiral into damage against the body's own cells.

Cancer cells can exploit these same brakes. Some tumors display proteins that directly engage a checkpoint on the T cell's surface, effectively tricking an approaching T cell into switching itself off before it attacks. Others exploit a related checkpoint that dampens T cell activity earlier in the immune response, before the cells even reach the tumor. Either way, the outcome is similar: a T cell that correctly identified a tumor as abnormal is talked out of attacking it.

The Neighborhood Around a Tumor

A tumor is never just a mass of cancer cells. It sits inside a mix of blood vessels, signaling molecules, and immune cells collectively called the tumor microenvironment, and that surrounding environment strongly influences whether an immune attack succeeds. Some of the immune cells drawn into this space are normally meant to calm immune responses down, and tumors can recruit unusually large numbers of them. Other recruited cells come from a different immune lineage and specialize in dampening the activity of nearby T cells and NK cells. Together, these cells can create a locally immune-suppressive zone around a tumor, even when the rest of the body's immune system is working normally elsewhere.

Inflammation adds a further wrinkle. Immune activity is often framed as something that opposes cancer, but chronic, low-grade inflammation in and around a tumor can do the opposite, encouraging tissue changes that help a tumor grow and spread. So immune cells inside a tumor aren't automatically working in the patient's favor. Their effect depends heavily on which cells are present and what signals surround them.

What Immune Cells Inside a Tumor Can Reveal

Despite that complexity, the presence of certain immune cells inside a tumor carries real information. Research on colorectal tumors has shown that the type, density, and location of infiltrating immune cells can predict a patient's clinical outcome, sometimes more strongly than standard tumor staging. A tumor heavily infiltrated by certain immune cells can behave differently than a similarly sized tumor with very few immune cells present. This pattern doesn't necessarily apply the same way across every cancer type, but it shows how much immune context can matter alongside size and spread.

Turning Biology Into Treatment

Understanding checkpoints opened a direct path to treatment. Drugs called checkpoint inhibitors block the brakes that tumors exploit, freeing T cells to resume their attack. A clinical trial of a drug blocking the earlier-acting checkpoint showed improved survival in patients with advanced melanoma, one of the first clear demonstrations that reactivating the immune system could meaningfully extend life. Related drugs targeting the other checkpoint pathway have since shown activity against a range of cancers, with durable responses reported in some patients.

A separate approach skips natural antigen recognition altogether. In CAR-T cell therapy, a patient's own T cells are removed and genetically modified in the lab to carry a new receptor built to recognize a specific target on cancer cells. Once reinfused, these engineered cells no longer depend on antigen display through MHC to find their target. This approach has produced durable remissions in certain blood cancers, one of the clearest examples so far of engineering immune recognition rather than simply restoring it.

Why It Doesn't Work the Same Way for Everyone

None of these approaches is universally effective, which fits with how much tumor biology varies from one cancer to another. A tumor that has already lost its surface display, recruited heavily suppressive cells into its surroundings, and leaned on several checkpoint pathways presents a very different challenge than one still caught in an earlier equilibrium. Checkpoint inhibitors depend on T cells already being present and able to recognize the tumor in the first place. If few immune cells have infiltrated a tumor to begin with, there may be little for the drug to unleash. CAR-T therapy, built around a single engineered target, tends to work best against cancers with a fairly consistent surface marker, which has so far made it most successful against certain blood cancers rather than solid tumors.

Cancer immunology remains an active field largely because these mechanisms interact in ways still being mapped out. What's established is that the relationship between a tumor and the immune system is neither fixed nor simple. It shifts over time, differs by cancer type, and depends on details inside and around individual tumor cells that researchers continue to work through.